CD33 is a transmembrane receptor stimulated by sialic acid residues that is expressed in approximately 85% of AML cases.216 CD33 undergoes internalization and dimerization upon binding, making it an attractive therapy and drug delivery target. This evidence concerns the gene CD33 and acute myeloid leukemia.